10-Q · May 11, 2026
AmBase Corporation's Q1 2026 results show a reduced net loss of $775,000 ($0.01 per share), improving from a net loss of $1,592,000 ($0.02 per share) in Q1 2025. Management continues to highlight substantial doubts…
Earnings analysis · 10-Q
ABCP earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the condensed statements of operations, balance sheets, cash flows, or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be…
Read full summary
The supplied 10-Q extract does not include the condensed statements of operations, balance sheets, cash flows, or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be quantified. The filing states that there were no material changes to previously disclosed risk factors and reports 0 year-to-date 2026 repurchases under a 10 million-share authorization. Continued disclosure of litigation funding agreements and the absence of quantitative guidance leave litigation, liquidity, and financing uncertainty as the primary signals.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
No Year-to-Date Share Repurchases
The company’s repurchase plan authorizes purchases of up to 10 million common shares, but no shares were repurchased year to date in 2026.
-
Litigation Funding Agreements Disclosed
The filing includes 2 litigation funding agreements as exhibits: one with Richard A. Bianco and one with BARC Investments LLC.
-
Quarterly Filing Completed
The filing was signed on August 12, 2026, for the quarter ended June 30, 2026.
What to watch
-
No Capital Return Activity
The company reported 0 shares repurchased under its 10 million-share repurchase authorization during year-to-date 2026, indicating no evidence of capital return in the period.
-
Existing Risks Remain Unchanged
Item 1A states there were no material changes to the risk factors disclosed in the 2025 Form 10-K; therefore, the filing does not reduce previously disclosed risks, including litigation and liquidity concerns.
-
Continued Litigation Financing Dependence
The filing identifies 2 litigation funding agreements and includes a July 31, 2026 letter agreement as an exhibit, underscoring continued reliance on litigation-related financing arrangements.
Management's outlook
No quantitative revenue or EPS outlook is provided in the supplied 10-Q extract; the filing does not establish guidance.
Earlier filings 4
10-K · March 30, 2026
AmBase is a small holding company whose December 31, 2025 assets are described as consisting “primarily of cash and cash equivalents,” with historic exposure to a disputed equity interest in the 111 West 57th Street…
10-Q · November 6, 2025
AmBase reported no revenue and a narrower Q3 2025 net loss of $(1,091) (basic EPS $(0.01)) versus a Q3 2024 loss of $(1,533) (EPS $(0.02)). Operating expenses continued to decline — $985 in Q3 2025 versus $1,523 in Q3…
10-Q · August 13, 2025
AmBase reported no revenue and a Q2 2025 net loss of $(1,083) (three months), with basic EPS of $(0.01), versus a Q2 2024 net loss of $(1,935) and EPS $(0.02). Operating expenses and operating loss narrowed…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.